Maxim Group analyst Jason McCarthy maintained a Buy rating on Agile Therapeutics (AGRX) yesterday and set a price target of $3. The company’s shares opened today at $1.33.
McCarthy observed:
“Agile announced that the FDA has accepted for review the NDA resubmission for Twirla, the company’s low-dose combined hormonal contraceptive patch. The resubmission addresses issues from the 2017 CRL (complete response letter) and is a class 2 response with a 6-month review; PDUFA November 16, 2019.”
According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -13.1% and a 25.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Currently, the analyst consensus on Agile Therapeutics is a Moderate Buy with an average price target of $3.50.
See today’s analyst top recommended stocks >>
Based on Agile Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.67 million. In comparison, last year the company had a GAAP net loss of $6.83 million.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
